API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MBRC-101 (monomethyl auristatin E)is a novel, targeted ADC which targets the EphA5 receptor tyrosine kinase. It is under phase 1 clinical development for the treatment of multiple solid tumor cancers, including breast, non-small cell lung and other solid tumors.
Lead Product(s): Monomethyl Auristatin E
Therapeutic Area: Oncology Product Name: MBRC-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023